Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | F11 | P03951 | 4/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938433 | 0.80 | ROCK2 (0.43) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL938434 | 0.80 | ROCK2 (0.43) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL1754080 | 0.78 | F11 (0.71) | F11KLKB1 | |
| SCHEMBL2106205 | 0.78 | F11 (0.71) | F11KLKB1 | |
| SCHEMBL4146643 | 0.77 | ROCK2 (0.43) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL1196662 | 0.75 | ROCK2 (0.48) | ROCK2KDM4EALDH1A1F11KLKB1 | |
| SCHEMBL1196664 | 0.75 | ROCK2 (0.48) | ROCK2KDM4EALDH1A1F11KLKB1 | |
| SCHEMBL13554564 | 0.75 | ROCK2 (0.48) | ROCK2KDM4EALDH1A1BRD4F11 | |
| SCHEMBL4150983 | 0.75 | ASIC3 (0.49) | KDM4EALDH1A1F11PRKACAPRKACG | |
| SCHEMBL9724160 | 0.70 | KDM4E (0.64) | KDM4EALDH1A1BRD4TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | claimed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | ROCK2 653/4885KDM4E 1947/4885ALDH1A1 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.